Akebia Therapeutics, Inc. Contracts & Agreements

Amendment #1 to License Agreement, dated August 30, 2024, by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SAS (Filed With SEC on November 7, 2024)

Amendment #1 to Supply Agreement, dated October 15, 2024, by and between the Company and STA Pharmaceutical Hong Kong Limited (Filed With SEC on November 7, 2024)

Seventh Amend (Filed With SEC on August 8, 2024)

Amendment #2 to Supply Agreement, dated as of April 15, 2024, by and between the Company and STA Pharmaceutical Hong Kong Limited (Filed With SEC on August 8, 2024)

Amendment #1 to Second Amended and Restated License Agreement, dated May 3, 2024, by and between the Company and Vifor (International) Ltd (Filed With SEC on August 8, 2024)

Termination and Settlement Agreement, dated July 10, 2024, by and between the Company and Vifor (International) Ltd (Filed With SEC on August 8, 2024)

Amendment #1 t (Filed With SEC on August 8, 2024)

Separation Agreement (Filed With SEC on May 9, 2024)

Form of Warrant (Filed With SEC on March 14, 2024)

Third Amended and Restated Non-Employee Director Compensation Program, effective January 1, 2024 (Filed With SEC on March 14, 2024)

Form of Officer Executive Severance Agreement (Reflecting Clawback Policy) (Filed With SEC on March 14, 2024)

Form of Officer Cash Bonus Agreement (Reflecting Clawback Policy) (Filed With SEC on March 14, 2024)

Form of Officer Stock Option Agreement under 2023 Stock Incentive Plan (Reflecting Clawback Policy) (Filed With SEC on March 14, 2024)

Form of Officer Restricted Stock Unit Agreement under 2023 Stock Incentive Plan (Reflecting Clawback Policy) (Filed With SEC on March 14, 2024)

Form of Officer Inducement Award Stock Option (Filed With SEC on March 14, 2024)

February 2024 Amendment to Retention and Separation Agreement for Nicole R. Hadas (Filed With SEC on March 14, 2024)

February 2024 Amendment to Retention and Separation Agreement for Michel Dahan (Filed With SEC on March 14, 2024)

Fourth Amendment to Loan Agreement dated as of October 31, 2023, by and among the Company, BioPharma Credit PLC, BPCR Limted Partnership, and BioPharma Credit Investments V... (Filed With SEC on March 14, 2024)

Agreement for the Provision of a Loan Facility dated January 29, 2024 between the Company and Kreos Capital VII (UK) Limited (Filed With SEC on March 14, 2024)

Warrant Agreement dated January 29, 2024 by and between the Company and Kreos Capital VII Aggregator SCSp (Filed With SEC on March 14, 2024)

October 2023 Amendment to Retention and Separation Agreement for Nicole R. Hadas (Filed With SEC on November 8, 2023)

License Agreement, dated May 24, 2023, by and between the Company and MEDICE Arzneimittel Ptter GmbH & Co. KG (Filed With SEC on August 28, 2023)

Third Amendment to Loan Agreement, dated as of June 30, 2023, by and among the Company, Biopharma Credit plc, B (Filed With SEC on August 28, 2023)

Packaging Validation Transfer Agreement, dated April 20, 2023, by and between the Company and Otsuka Pharmaceutical Co. Ltd (Filed With SEC on August 28, 2023)

Form of May 2023 Amendment to Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas (Filed With SEC on August 28, 2023)

July 2023 Amendment to Retention and Separation Agreement for Michel Dahan (Filed With SEC on August 28, 2023)

July 2023 Amendment to Retention and Separation Agreement for Nicole R. Hadas (Filed With SEC on August 28, 2023)

Separation Agreement with David Spellman, dated June 9, 2023 and Amendment to Separation Agreement dated July 6, 2023 (Filed With SEC on August 28, 2023)

Second Amended and Restated Non-Employee Director Compensation Program, effective June 6, 2023 (Filed With SEC on August 28, 2023)

Form of Non-Employee Director Stock Option Agreement under 2023 Stock Incentive Plan (Filed With SEC on August 28, 2023)

Form of Officer Stock Option Agreement under 2023 Stock Incentive Plan (Filed With SEC on August 28, 2023)

Form of Non-Employee Director Restricted Stock Unit Agreement under 2023 Stock Incentive Plan (Filed With SEC on August 28, 2023)

Form of Officer Restricted Stock Unit Agreement under 2023 Stock Incentive Plan (Filed With SEC on August 28, 2023)

Form of Officer Inducement Award Stock Option Agreement under 2023 Stock Incentive Plan (Filed With SEC on August 28, 2023)

Amended and Restated (Filed With SEC on May 8, 2023)

Amendment No. 5 (Filed With SEC on May 8, 2023)

Form of Stock Appreciation Rights Award Agreement for officers (Filed With SEC on May 8, 2023)

Amendment No. 1 to Collaboration Agreement, dated December 2, 2022, by and between Akebia Therapeutics, Inc. and Mitsubishi Tanabe Pharma Corporation (Filed With SEC on March 10, 2023)

Termination and Settlement Agreement, dated December 22, 2022, by and between Keryx Biopharmaceuticals, Inc. and BioVectra Inc (Filed With SEC on March 10, 2023)

License Agreement, dated December 22, 2022, by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SAS (Filed With SEC on March 10, 2023)

Form of Amendment to Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas (Filed With SEC on November 3, 2022)

Retention Agreement with David Spellman, dated June 22, 2022 (Filed With SEC on August 4, 2022)

Form of Officer Restricted Stock Unit Award Agreement (Filed With SEC on August 4, 2022)

Form of Officer Non-Statutory Stock Option Agreement under 2014 Incentive Plan (Filed With SEC on August 4, 2022)

Termination and Settlement Agreement, dated (Filed With SEC on August 4, 2022)

Second Amendment and Waiver, dated July 15, 2022, by and among the Company, Biopharma Credit plc, BCPR Limited Partnership and Biopharma Credit Investments V (Master) LP (Filed With SEC on August 4, 2022)

Form of Officer Retention Letter Agreement (Filed With SEC on May 9, 2022)

Form of Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas (Filed With SEC on May 9, 2022)

Separation Agreement with Dell Faulkingham, dated May 5, 2022 (Filed With SEC on May 9, 2022)

Open Market Sale AgreementSM, dated April 7, 2022, by and between Akebia Therapeutics, Inc. and Jefferies LLC (Filed With SEC on April 7, 2022)

Investment Agreement between Akebia Therapeutics, Inc. and Vifor (International) Ltd., dated February 18, 2022 (Filed With SEC on March 1, 2022)

First Amendment to One Marina Park Drive Office Lease, dated February 24, 2022, by and between Keryx Biopharmaceuticals, Inc. and CLPF One Marina Park Drive LLC... (Filed With SEC on March 1, 2022)

Assignment and Assumption Agreement, dated February 24, 2022, by and between Keryx Biopharmaceuticals, Inc. and Akebia Therapeutics, Inc (Filed With SEC on March 1, 2022)

Amended and Restated Cash Incentive Plan, effective January 19, 2022 (Filed With SEC on March 1, 2022)

Collaboration Agreement between Akebia Therapeutics, Inc. and Mitsubishi Tanabe Pharma Corporation, dated December 11, 2015 (Filed With SEC on March 1, 2022)

Second Amended and Restated License Agreement, dated (Filed With SEC on March 1, 2022)

Master Manufacturing Services Agreement by and between Keryx Biopharmaceuticals, Inc. and Patheon Manufacturing Services LLC and certain of its affiliates, dated September 27,... (Filed With SEC on March 1, 2022)

Amendment No. 4 to Master Manufacturing Services and Supply Agreement, dated as of December 17, 2021, by and between Siegfried Evionnaz SA and Keryx Biopharmaceuticals, Inc (Filed With SEC on March 1, 2022)

First Amendment and (Filed With SEC on March 1, 2022)

Form of Officer Performance-Based Stock Option Award, under the Company's 2014 Incentive Plan, as amended (Filed With SEC on November 4, 2021)

Form of Officer Performance-Based Restricted Stock Unit Award, under the Company's 2014 Incentive Plan, as amended (Filed With SEC on November 4, 2021)

Form of Officer Cash Bonus Letter Agreement (Filed With SEC on November 4, 2021)

Amendment #1 to the Supply Agreement, dated as of April 15, 2021, by and between Akebia Therapeutics, Inc, and STA Pharmaceutical Hong Kong Limited (Filed With SEC on August 5, 2021)

Supply Agreement, dated February 10, 2021, by and between the Company and STA Pharmaceutical Hong Kong Limited (Filed With SEC on May 10, 2021)

Royalty Interest Acquisition Agreement, dated February 25, 2021, by and between the Company and HealthCare Royalty Partners IV, L.P (Filed With SEC on May 10, 2021)

Description of Registrants Securities (Filed With SEC on February 25, 2021)

Sixth Amendment to Office Lease Agreement Between CLPF-Cambridge Science Center, LLC and Akebia Therapeutics, Inc. dated November 30, 2020 (Filed With SEC on February 25, 2021)

Non-Employee Director Compensation Program, effective January (Filed With SEC on February 25, 2021)

Amendment No. 1 to Master Manufacturing Services and Supply Agreement, dated as of December 21, 2020, by and between Siegfried Evionnaz SA and Keryx Biopharmaceuticals, Inc (Filed With SEC on February 25, 2021)

Amendment No. 2 to Master Manufacturing Services and Supply Agreement, dated as of January 29, 2021, by and between Siegfried Evionnaz SA and Keryx Biopharmaceuticals, Inc (Filed With SEC on February 25, 2021)

Amendment No. 3 to Master Manufacturing Services and Supply Agreement, dated as of February 11, 2021, by and between Siegfried Evionnaz SA and Keryx Biopharmaceuticals, Inc (Filed With SEC on February 25, 2021)

Consulting Agreement (Filed With SEC on November 5, 2020)

Amended and Restated Product Manufacture and Supply and Facility Construction Agreement between BioVectra, Inc. and Keryx Biopharmaceuticals, Inc., dated September 4, 2020 (Filed With SEC on September 11, 2020)

Offer Letter to David Spellman, dated as of June 13 (Filed With SEC on August 10, 2020)

Supply Agreement, dated as of April 2, 2020, by and between Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited (Filed With SEC on August 10, 2020)

Underwriting Agreement, dated May 11, 2020, by and among Akebia Therapeutics, Inc. and J.P. Morgan Securities LLC and Piper Sandler & Co., as representatives of the several... (Filed With SEC on May 12, 2020)

Supply Agreement, dated as of March 11, 2020, by and between Akebia Therapeutics, Inc. and Patheon, Inc (Filed With SEC on May 5, 2020)

Description of Registrants Securities (Filed With SEC on March 12, 2020)

Guaranty and Security Agreement, dated November 25, 2019, by and between the Company, Keryx Biopharmaceuticals, Inc. and Biopharma Credit plc (Filed With SEC on March 12, 2020)

Loan Agreement, dated November 11, 2019, by and among the Company, Keryx Biopharmaceuticals, Inc., Biopharma Credit plc and Biopharma Credit Investments V (Master) LP (Filed With SEC on March 12, 2020)

Sublease, dated as of September 9, 2019, by and between Keryx Biopharmaceuticals, Inc. and Foundation Medicine, Inc (Filed With SEC on November 12, 2019)

Waiver and First Amendment to Loan Security and Security Agreement, dated as of July 31, 2019, by and between Keryx Biopharmaceuticals, Inc. and Silicon Valley Bank (Filed With SEC on November 12, 2019)

Security Agreement, dated as of August 7, 2019, by and between Akebia Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on November 12, 2019)

Unconditional Guaranty, dates as August 7, 2019, by and between Akebia Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on November 12, 2019)

Controlled Equity OfferingSM Amended and Restated Sales Agreement, dated as of November 12, 2019, by and between the Company and Cantor Fitzgerald & Co (Filed With SEC on November 12, 2019)

Second Amended and Restated License Agreement, dated as of April 17, 2019, by and between Akebia Therapeutics, Inc. and Panion & BF Biotech, Inc (Filed With SEC on August 8, 2019)

Supply Agreement, dated as of April 9, 2019, by and between Akebia Therapeutics, Inc. and Esteve Qumica, S.A (Filed With SEC on August 8, 2019)

Master Consulting Services Agreement, dated as of June 10, 2019, by and between Akebia Therapeutics, Inc. and Scott A. Canute (Filed With SEC on August 8, 2019)

Amended and Restated License Agreement, dated as of April 8, 2019, by and between Akebia Therapeutics, Inc. and Vifor (International) Ltd (Filed With SEC on August 8, 2019)

Form of Officer Restricted Stock Unit Award Agreement under 2014 Incentive Plan (Filed With SEC on March 26, 2019)

Amended and Restated Non-Employee Director Compensation Program, effective January 30, 2019 (Filed With SEC on March 26, 2019)

Letter Agreement by and between Panion & BF Biotech, Inc., the Company and Keryx Biopharmaceuticals, Inc. dated October 24, 2018 (Filed With SEC on March 26, 2019)

Form of Employee Agreement (Confidentiality, Non-Competition, Non-Solicitation and Development Agreement) applicable to officers (Filed With SEC on March 26, 2019)

Keryx Biopharmaceuticals, Inc. Director Non-Statutory Stock Option Award Terms and Conditions under the Third Amended and Restated Directors Equity Compensation Plan (Filed With SEC on March 26, 2019)

Exclusive Distribution Agreement between Keryx Biopharmaceuticals, Inc. and Cardinal Health 105, Inc., dated October 16, 2014 and Amendment to Exclusive Distribution Agreement... (Filed With SEC on March 26, 2019)

Manufacture and Supply Agreement between Keryx Biopharmaceuticals, Inc. and BioVectra Inc., dated May 26, 2017 and Amendment to Manufacture and Supply Agreement between Keryx... (Filed With SEC on March 26, 2019)

Registration Rights Agreement, dated December 12, 2018, by and between Akebia Therapeutics, Inc. and Baupost Group Securities, L.L.C (Filed With SEC on December 13, 2018)

First Amendment to Agreement and Plan of Merger dated October 1, 2018 (Filed With SEC on October 1, 2018)

Fifth Amendment to Office Lease Agreement Between CLPF-Cambridge Science Center, LLC and Akebia Therapeutics, Inc. dated April 9, 2018 (Filed With SEC on August 8, 2018)

Agreement and Plan of Merger, dated as of June 28, 2018, by and among Akebia Therapeutics, Inc., Alpha Therapeutics Merger Sub, Inc., and Keryx Biopharmaceuticals, Inc (Filed With SEC on June 28, 2018)

Notes Conversion Agreement, dated as of June 28, 2018, by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C (Filed With SEC on June 28, 2018)

Underwriting Agreement, dated March 22, 2018, between Akebia Therapeutics, Inc. and Morgan Stanley & Co. LLC, as underwriter (Filed With SEC on March 26, 2018)

Amendment No. 1 to Fourth Amended and Restated Investors Rights Agreement, dated June 28, 2017 (Filed With SEC on March 12, 2018)

Form of Director and Officer Indemnification Agreement (Filed With SEC on March 12, 2018)

Fourth Amendment to Office Lease Agreement Between CLPF-Cambridge Science Center, LLC and Akebia Therapeutics, Inc., dated May 1, 2017 (Filed With SEC on March 12, 2018)

Non-Employee Director Compensation Program (Filed With SEC on March 12, 2018)

Form of Restricted Stock Unit Award Agreement under 2014 Incentive Plan (Filed With SEC on March 12, 2018)

Offer Letter to Rita Jain, dated April 28, 2017 (Filed With SEC on March 12, 2018)

Letter Agreement between Akebia Therapeutics, Inc. and Mitsubishi Tanabe Pharma Corporation, dated September 26, 2017 (Filed With SEC on November 8, 2017)

Investment Agreement between Akebia Therapeutics, Inc. and Vifor (International) Ltd., dated May 12, 2017 (Filed With SEC on August 8, 2017)

4,000,000 Shares AKEBIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on June 29, 2017)

CONFIDENTIAL (Filed With SEC on May 9, 2017)

CONFIDENTIAL RESEARCH AND LICENSE AGREEMENT between AKEBIA THERAPEUTICS, INC. and Janssen Pharmaceutica NV Dated as of February 9, 2017 (Filed With SEC on May 9, 2017)

THIRD AMENDMENT TO LEASE (Filed With SEC on November 9, 2016)

SECOND AMENDMENT TO LEASE (Filed With SEC on March 14, 2016)

CONFIDENTIAL COLLABORATION AGREEMENT BY AND BETWEEN AKEBIA THERAPEUTICS, INC. AND MITSUBISHI TANABE PHARMA CORPORATION (Filed With SEC on March 14, 2016)

7,250,000 Shares AKEBIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on January 12, 2016)

MASTER SERVICES AGREEMENT (Filed With SEC on August 11, 2015)

AKEBIA THERAPEUTICS, INC. Shares of Common Stock (par value$0.00001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on August 11, 2015)

7,272,727 Shares AKEBIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on April 17, 2015)

FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT TABLE OF CONTENTS (Filed With SEC on March 4, 2015)

FIRST AMENDMENT TO LEASE (Filed With SEC on March 4, 2015)

Restricted Stock Unit Award granted under the AKEBIA THERAPEUTICS, INC. 2014 Incentive Plan Restricted Stock Unit Award Agreement (Filed With SEC on March 4, 2015)

Shares AKEBIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on March 4, 2014)

FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT TABLE OF CONTENTS (Filed With SEC on March 4, 2014)

AKEBIA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on March 4, 2014)

STOCK OPTION AWARD granted under the AKEBIA THERAPEUTICS, INC. 2014 INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on March 4, 2014)

OFFICER STOCK OPTION AWARD granted under the AKEBIA THERAPEUTICS, INC. 2014 INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on March 4, 2014)

NON-EMPLOYEE DIRECTOR STOCKOPTION AWARD granted under the AKEBIA THERAPEUTICS, INC. 2014 INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on March 4, 2014)

AKEBIA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (Filed With SEC on March 4, 2014)

EXECUTIVE SEVERANCE AGREEMENT (Filed With SEC on March 4, 2014)

AKEBIA THERAPEUTICS, INC. 2014 INCENTIVE PLAN (Filed With SEC on March 4, 2014)

AKEBIA THERAPEUTICS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on March 4, 2014)

AKEBIA THERAPEUTICS, INC. CASH INCENTIVE PLAN (Filed With SEC on March 4, 2014)

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on March 4, 2014)

THIRDAMENDED AND RESTATED VOTING AGREEMENT TABLE OF CONTENTS (Filed With SEC on February 14, 2014)

AMENDMENT NO. 1 TO THETHIRD AMENDED AND RESTATED VOTING AGREEMENT (Filed With SEC on February 14, 2014)

THIRDAMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT TABLE OF CONTENTS (Filed With SEC on February 14, 2014)

AMENDMENT NO. 1 TO THETHIRD AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on February 14, 2014)

SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (Filed With SEC on February 14, 2014)

AMENDMENT NUMBER ONE TO SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (Filed With SEC on February 14, 2014)

AMENDMENT NUMBER TWO TO THE SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (Filed With SEC on February 14, 2014)

CAMBRIDGE SCIENCE CENTER AND 245 FIRST STREET CAMBRIDGE, MASSACHUSETTS OFFICE LEASE AGREEMENT BETWEEN MA-RIVERVIEW/245 FIRST STREET, L.L.C. a Delaware limited liability company... (Filed With SEC on February 14, 2014)

AMENDED AND RESTATED ADMINISTRATIVE SERVICES AGREEMENT (Filed With SEC on February 14, 2014)

ADMINISTRATIVE SERVICES AGREEMENT (Filed With SEC on February 14, 2014)

AKEBIA THERAPEUTICS, INC. AMENDED AND RESTATED 2008 EQUITY INCENTIVE PLAN ARTICLE I ESTABLISHMENT AND TERM (Filed With SEC on February 14, 2014)

AKEBIA THERAPEUTICS, INC. AMENDMENT NO. 1 TO AMENDED AND RESTATED 2008 EQUITY INCENTIVE PLAN Effective as of May 10, 2013 (Filed With SEC on February 14, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on February 14, 2014)

SEPARATION AGREEMENT (Filed With SEC on February 14, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on February 14, 2014)

Amendment No. 1 to EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on February 14, 2014)

CONSULTINGAGREEMENT (Filed With SEC on February 14, 2014)

SEPARATIONAGREEMENT (Filed With SEC on February 14, 2014)

Akebia Therapeutics, Inc. AMENDED AND RESTATED PARTIAL RECOURSE PROMISSORY NOTE (Filed With SEC on February 14, 2014)

FORGIVENESS AND RELEASE AGREEMENT (Filed With SEC on February 14, 2014)

Category

Industry

Companies

Contracts

Akebia Therapeutics, Inc. Contracts & Agreements